Myriad Genetic

MYGN

----

Current ValuationThe current P/E ratio is -3.66, below the reasonable range, cheaper than 98.85% of the time in the past 1 years, and the industry ranks 338/604, the industry Median -2.12.

-3.66xP/E

Stock price$4.31Earnings per share$-1.18

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-57.85x	148.64%	$187.44B
MRNAUSModerna	-28.51x	15.53%	$89.83B
CSLLYUSCSL Limited	-23.93x	--	$61.70B
NTRAUSNatera	-300.29x	6.99%	$57.76B
RVMDUSRevolution Medicines	-23.00x	62.39%	$40.67B
ROIVUSRoivant Sciences	-96.15x	146.49%	$25.60B
BNTXUSBioNTech SE	-12.44x	19.72%	$24.36B
INSMUSInsmed	-25.10x	74.21%	$21.97B
SMMTUSSummit Therapeutics	-16.39x	19.55%	$14.03B
BBIOUSBridgebio Pharma	-18.47x	28.48%	$12.78B
IBRXUSImmunityBio	-11.22x	151.32%	$11.14B
MDGLUSMadrigal Pharma	-33.53x	51.06%	$10.90B
PCVXUSVaxcyte	-9.98x	49.36%	$10.62B
TWSTUSTwist Bioscience	-76.94x	28.88%	$10.52B
KYMRUSKymera Therapeutics	-31.20x	5.25%	$9.35B
ARWRUSArrowHead Pharma	-27.70x	36,308.30%	$8.86B
CYTKUSCytokinetics	-9.78x	6.46%	$8.75B
ABVXUSAbivax SA	-16.50x	22.49%	$7.68B
SYREUSSpyre Therapeutics	-50.30x	46.89%	$7.56B
IONSUSIonis Pharma	-13.31x	50.60%	$7.52B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.